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Aims Atherosclerosis is a chronic inflammatory disease occurring within the artery wall. A crucial step in atherogenesis is the infiltra-
tion and retention of monocytes into the subendothelial space of large arteries induced by chemokines and growth factors.
Angiopoietin-1 (Ang-1) regulates angiogenesis and reduces vascular permeability and has also been reported to promote mono-
cyte migration in vitro. We investigated the role of Ang-1 in atherosclerosis-prone apolipoprotein-E (Apo-E) knockout mouse.
....................................................................................................................................................................................................
Methods
and results
Apo-E knockout (Apo-E-/-) mice fed a western or normal chow diet received a single iv injection of adenovirus
encoding Ang-1 or control vector. Adenovirus-mediated systemic expression of Ang-1 induced a significant increase
in early atherosclerotic lesion size and monocyte/macrophage accumulation compared with control animals receiv-
ing empty vector. Ang-1 significantly increased plasma MCP-1 and VEGF levels as measured by ELISA. FACS analysis
showed that Ang-1 selectively increased inflammatory Gr1þmonocytes in the circulation, while the cell-surface
expression of CD11b, which mediates monocyte emigration, was significantly reduced.
....................................................................................................................................................................................................
Conclusions Ang-1 specifically increases circulating Gr1þ inflammatory monocytes and increases monocyte/macrophage reten-
tion in atherosclerotic plaques, thereby contributing to development of atherosclerosis.
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1. Introduction
Atherosclerosis is a chronic inflammatory disease of the artery wall.1–3
Monocyte-derived macrophages participate in a maladaptive, non-
resolving inflammatory response that expands the subendothelial layer
due to the accumulation of cells, lipid and matrix.4 Signals such as mono-
cyte chemoattractant protein-1 (MCP-1) increase monocyte recruit-
ment into atherogenic foci,5,6 in particular, Ly6Chigh(Gr1þ) inflammatory
monocytes that gives rise to macrophages in atheromata.7
Angiopoietin-1 (Ang-1) and its cognate receptor Tie2 are well-
established regulators of vascular development and angiogenesis.8–10
Ang-1 plays a crucial role in endothelial cell survival, vessel wall remodel-
ling and mural cell recruitment.11 Overexpression of Ang-1 dramatically
blocks increases in vascular permeability induced by VEGF,12,13 suggest-
ing that it has protective properties in the microvasculature.14 However,
long-term Ang-1 expression using adeno-associated virus failed to pro-
tect against the development of rat cardiac allograft arteriosclerosis.15
Jeansson et al.8 recently reported that Ang-1 is not necessary for normal
steady-state physiological processes in the adult, being expendable in the
blood vasculature from E13.5 onwards,10 but when combined with
injury, Ang-1 deficiency results in accelerated angiogenesis and fibrosis.10
Long et al.14 have reported that Ang-1 therapy accompanied pro-fibrotic
and inflammatory effects in folic acid-induced tubular necrosis and in a
murine model of acute renal injury.16 More importantly, Ang-1 is
expressed at a higher level in atherosclerotic lesions obtained from
endarterectomy of the carotid artery compared to healthy controls.17
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Furthermore, Ang-1 stimulates TNF-a, a key cytokine that modulates
the inflammatory process of atherosclerosis.18 expression in peripheral
blood mononuclear cells,19 Indeed, we and others have demonstrated
that Ang-1 stimulates monocyte20 and neutrophil21 migration, both of
which are the critical players in atherosclerosis,22,23 implicating Ang-1 as
a potential player in monocyte recruitment and retention mechanisms
especially in a high-lipid environment.
Based on these observations, we hypothesized that Ang-1 plays a role
in the progression of atherosclerosis in a hypercholesterolaemic environ-
ment through its effects on inflammatory monocytes. In this study, we
demonstrate that high circulating Ang-1 levels promote a pro-atherogenic
phenotype by specifically increasing Gr1þ inflammatory monocytes and
elevating the circulating levels of pro-remodelling cytokines, VEGF and
MCP-1 in ApoE-/- mice. Furthermore, Ang-1-induced monocyte/macro-
phage retention in atherosclerotic plaques was accompanied by decreased
cell-surface expression of CD11b on circulating monocytes.
2. Methods
2.1 Adenoviruses
Recombinant adenovirus encoding human Ang-1* (AdAng-1) was provided
by Regeneron Pharmaceuticals (Tarrytown, New York, USA), propagated
in Human embryonic kidney cells 293 (HEK293), purified on CsCl gradients,
titered, and stored at80 C in 4% sucrose buffer. Control, empty adenovi-
rus (AdEV) was generated as described previously.22
2.2 Adenovirus-mediated expression of
Ang-1 in ApoE-/- mice
All procedures conformed to the recommendations of the Guide for the
Care and Use of Laboratory Animals published by the US National
Institutes of Health (NIH Publication, 8th Edition, 2011) and also in
accordance with Directive 2010/63/EU of the European Parliament and
with the UK Home Office Animal (Scientific Procedures) Act 1986. All
procedures passed local ethical review. Eight- to nine-week-old male
ApoE-/- mice on a C57BL/6J background (B6.129P2-apoEtm1Unc, SN:
002052; Jackson Labs, Maine, USA) were maintained with a 12-hour light/
dark cycle and had free access to food and water. To investigate the
effects of Ang-1 on atherosclerosis under high-fat environment, the mice
were fed a western-style diet (TD 88137; Harlan Teklad, South Easton,
MA, USA) for 1 week and then divided into two groups (n¼ 12 per
group) and injected via tail vein with 5  109 pfu of AdAng-1 or control
empty virus (AdEV) diluted into 100 lL PBS. These mice were maintained
on a western diet for another 4 weeks. In another sets of experiments,
mice fed a normal chow diet (n¼ 5 in each group in each experiment).
These mice were injected with 5 109 pfu of AdAng-1 or control empty
virus (AdEV) diluted into 100 lL PBS through tail vain. The mice were
euthanized 4 weeks after virus delivery. Briefly, cardiac puncture was per-
formed with 2.3% isoflurane inhalation, and blood was collected in EDTA
tube. Mice were injected with Pentabarbitone (Euthatal, 270 mg/kg, ip
injection) to euthanize and then perfuse-fixed with 1% paraformaldehyde.
Heart and proximal aortae were harvested. Serial 5 mm frozen sections of
the aortae were prepared as described previously.24 For the evaluation of
atherosclerotic lesions, nine sections were taken at 40 mm intervals,
stained with oil red O, counterstained with Mayer’s hematoxylin, and the
lesions were quantified using NIH Image software (v. 1.62). The mean
area in nine sections was determined for each animal. Up to three sec-
tions from each animal were immunostained for monocytes/macro-
phages using a monoclonal rat anti-mouse monocyte/macrophage
antibody (MOMA-2, BD PharMingen) and quantification of MOMA-2-
positive area was performed. The mean MOMA-2-positive area was
determined for each animal. The aortic arches were available from some
animals and Sudan IV en face staining was performed for analysis of lipid
accumulation, as described elsewhere.25 Blood was taken at 3 and 10
days after virus injection by tail bleed and at 28 days by cardiac puncture.
2.3 Aortic ring culture
Male ApoE-/- mice (8–10 weeks old) were euthanized and bled out.
Thoracic aortas were removed into a Petri dish filled with cold sterile
PBS and aortas were mechanically cleaned of surrounding fat tissue.
Using a surgical blade, aortas were evenly cut into 1 mm rings, which
were transferred to fresh DMEM medium supplemented with 1% fetal
calf serum (FCS), penicillin and streptomycin. Aortic rings were stimu-
lated with Ang-1 (400 ng/mL; R&D Systems, Abingdon, UK) for 24 hours
at 37 C. Some of rings were pre-incubated with Tie2 blocking peptide26
(NLLMAAS, 100 mM; Peptide Protein Research Ltd, Hampshire, UK) for
30 min prior to stimulation with Ang-1. Each condition was performed in
duplicates. Commercial ELISA as described below measured the levels
of MCP-1 and VEGF in the conditioned medium.
2.4 ELISA assay
Whole blood was collected into EDTA-containing tubes. ELISA was used
to measure plasma levels of Ang-1, MCP-1 and VEGF (R&D Systems).
2.5 Immunohistochemistry
Immunohistochemistry was performed on serial frozen sections.
Primary rat anti-mouse antibodies to monocyte/macrophage (MOMA-
2), and CD31 were from BD Pharmingen. Isotype-matched non-binding
immunoglobulin was used as a negative control. Binding of secondary
antibodies (Vector Laboratories, Peterborough, UK) was detected with
Vectastain ABC reagent (Vector Laboratories, Peterborough, UK) and
DAB substrate kits (Dako, Cheadle, UK). Cells were counterstained
with Mayer’s hematoxylin.
2.6 Flow cytometry
Whole-blood samples (15 lL) were washed with cold PBS before incu-
bating for 20 min on ice with directly conjugated antibodies: anti-Ly6C-
APC (eBioscience, Cheshire, UK), anti-CD11b (eBioscience, Cheshire,
UK) and anti-Ly6G (Gr1)-FITC (eBioscience, Cheshire, UK). Monocytes
were gated according to CD11b expression and side scatter and then
further separated by Gr1 and Ly6C staining. Two monocyte subsets
were identified as SSClowCD11bþGr1þ Ly6Chigh and
SSClowCD11bþGr1-Ly6Clow monocytes, whereas neutrophils were
identified as SSChighCD11bþGr1highLy6Cinte (Figure 3A and B) using
FACSCalibur. Combination of anti-CD11b, anti-Gr1 and anti-Tie2-PE
(eBioscience, Cheshire, UK) were used to stain cells to analyse Tie2-
positive monocyte population.
2.7 Measurement of plasma Ang-1
Blood was collected from mice at days 0, 3, 7, 14, 21, and 28 after injec-
tion of AdEV (n¼ 3) or AdAng-1 (n¼ 3), mixed with EDTA. Plasma lev-
els of Ang-2 were determined a using specific ELISA following the
manufacturer’s instructions (R&D Systems, MN, USA).
2.8 Confocal immunofluorescence staining
Tissue sections were stained with rat monoclonal anti-Ly6C (IgG2c;
eBioscience, Paisley, UK) followed by Alexa Fluor 568-conjugated anti-
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.rat IgG (Invitrogen, Paisley, UK). Then counter stained with anti-CD11b-
FITC (eBioscience, Cheshire, UK) followed by goat anti-FITC-
conjugated with Alexa Fluor488 (Invitrogen, Paisley, UK). Sections were
washed with PBS, coverslip mounted and imaged on a Leica SP5C
inverted confocal laser scanning microscope.
2.9 Statistical analysis
Results are expressed as the mean6 SEM. Comparisons between two
groups were performed using unpaired Student’s t-tests, and compari-
sons among multiple groups were performed using One-way Analysis of
variance (ANOVA). Statistical analyses were performed using Prism 7.0
(GraphPad Software, Inc., La Jolla, CA, USA). P values<0.05 were con-
sidered statistically significant.
3. Results
3.1 Ang-1 enhances atherosclerotic plaque
formation in ApoE-/- mice fed a western
diet
To investigate the effect of Ang-1 on atherosclerosis development,
ApoE-/- mice fed a western diet for 1 week were given AdAng-1 or con-
trol AdEV injection and maintained on a western diet for a further 4
weeks. It has been demonstrated that iv delivery of adenovirus leads to a
widespread distribution of vector with the highest level of expression in
the liver.27 The level of Ang-1 in plasma peaked 3 days after injection
and remained elevated for >10 days (Supplementary material online,
Figure S1). No significant differences in body weight or circulating lipid
profiles were detected between these groups (Supplementary material
online, Table S1). Four weeks after systemic adenovirus administration,
atherosclerotic lesions were analysed in aortas sections using oil red O
staining (Figure 1A). Systemic overexpression of Ang-1 significantly
increased the mean atherosclerotic lesion size compared with AdEV-
infected ApoE-/- mice (0.6876 0.071 mm2 vs. 0.4376 0.045 mm2; P< 0.
01; Figure 1B). Uninfected ApoE-/- mice had lesions similar in size to the
AdEV-infected group (0.5476 0.05 mm2, data not shown). In addition,
with macrophages being a primary cell type contributing to development
of the atherosclerotic lesion, we examined the effect Ang-1 on mono-
cyte/macrophage accumulation in atherosclerotic lesion using monocyte/
macrophage marker MOMA-2. As expected, Ang-1 induced a significantly
increased monocyte/macrophage accumulation in lipid lesions compared
with control animals receiving empty vector (0.156 0.015 mm2 vs. 0.
096 0.021 mm2; P< 0.05; Figure 1C). Endothelium staining using CD31
antibody showed no significant vascularization in aortas (Figure 1A)
3.2 Ang-1 promotes atherosclerotic
plaque formation in ApoE-/- mice fed a
normal chow diet
In order to further confirm the effects of Ang1 in atherosclerosis devel-
opment without the confounding effects of western diet on inflammation
in apoE-/- mice, AdAng-1 or control AdEV were injected in apoE-/- mice
fed a normal chow diet and en face analyses of Sudan IV-stained areas in
thoracic aortas were quantified 4 weeks after treatment. Ang-1 signifi-
cantly increased plaque area compared with AdEV-treated ApoE-/- mice
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Figure 1 Ang-1 enhances atherosclerotic plaque formation in ApoE-/- mice fed a Western diet. ApoE-/- mice fed a Western diet for 4 weeks were infected
systemically with adenoviruses encoding Ang1 (AdAng-1) or a control virus (AdEV). The mice were euthanized 4 weeks after adenovirus treatment and
effects on early to intermediate atherosclerotic lesions were investigated. (A) Representative sections stained with oil red O (top panel) and immunohisto-
chemical staining of monocytes/macrophages and endothelium with the MOMA-2 monoclonal antibody (middle panel) and CD31 antibody (bottom panel)
respectively in AdEV or AdAng1-treated ApoE-/- mice. Original magnification, 40 (Oil red), 100 (MOMA-2). Bars, 100 mm. (B) Atherosclerotic lesion
area was quantified by oil red O staining of lesions from serial aortic sections using ImageJ image analysis software. Nine serial sections at 40 mm intervals
were used from each animal for analysis. Results show the mean from nine cross-sectional lesion size (mm2) for each animal and the line indicates median
value per treatment of mice. *P< 0.01. (C) Similarly, five mice were randomly picked from each treatment group, and tissue sections from each animal were
analysed for MOMA-2-positive lesion area. *P<0.05.
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.(3.906 0.195 mm2 vs. 0.736 0.169 mm2; P< 0.01; Figure 2A and B). Oil
red O-positive atherosclerotic area and MOMA-2-positive area were
also analysed as before (Figure 2C and D). As expected, mice fed a normal
chow diet developed much smaller plaques compared with mice on a
western diet. However, the plaques were again significantly larger in the
AdAng-1-treated group compared to the AdEV-treated group
(0.206 0.034 mm2 vs. 0.116 0.024 mm2; P< 0.05; Figure 2C). Similarly,
the accumulation of MOMA-2-positive cells, which co-localized with oil
red O staining in the aortic root (Figure 1A), was also increased in the
AdAng-1-treated group (0.036 0.003 mm2 vs. 0.026 0.004 mm2;
P< 0.01; Figure 2D)
3.3 Ang-1 increases proportion of
circulating Gr1þ/Ly6Chigh monocytes
It is widely accepted that bone marrow-derived circulating monocytes
play an important role in atherosclerosis28 and that different subsets of
monocytes commit for specific functions while still in the circulation.29
Particularly, Ly6Chigh(Gr1þ) inflammatory monocytes give rise to mac-
rophages in atheromata.7 To investigate the role of Ang-1 on the
dynamics of monocyte turnover/recruitment, peripheral monocytes in
ApoE-/- mice fed a normal chow diet were evaluated at different time
points after AdAng-1 treatment (3, 10 and 28 days). Monocytes were
gated according CD11bþand SSC (Figure 3A R1) and two monocyte
subsets were identified as SSClowCD11bþGr1þ Ly6Chigh (Figure 3A
R3) and SSClowCD11bþGr1-Ly6Clow monocytes (Figure 3A R2),
which correspond to inflammatory and residential subsets,
respectively.30 A third CD11bþcells population with high SSC, low
Ly6C are neutrophils (Figure 3A R4).7,30 The proportion of circulating
Gr1þmonocytes in AdAng-1-treated mice was significantly increased
at day 10 compared with AdEV-treated mice (4.956 0.503 vs.
2.936 0.163; P< 0.01), whereas Gr1- monocytes remained
unchanged (Figure 3B). Interestingly, neutrophil proportion was also
increased (9.536 3.92 vs. 13.746 4.04; P< 0.05). Significant increase
in the ratio of Gr1þ/Gr1- monocytes (Figure 3C) was positively corre-
lated with plaque size (Figure 3D), indicating the importance of mono-
cyte subsets balance in disease progression. At day 3 and day 28, the
proportions of Gr1- and Gr1þmonocytes showed no differences
between AdEV and AdAng-1 treated groups (data not shown).
Furthermore, immunostaining of aorta obtained from ApoE-/- mice
received AdAng-1 treatment revealed that Ly6C-positive cells local-
ized in the plaques (Figure 4) in line with the current understanding
that this group of cells is likely to account for the observed accumula-
tion of monocytes/macrophages in the plaques.
It is believed that inflammatory monocytes derived from bone mar-
row play a crucial role in atherogenesis. Recently, spleen has been
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Figure 2 Ang-1 promotes early atherosclerotic plaque formation in ApoE-/- mice fed a normal chow diet. ApoE-/- mice fed a normal chow diet were
infected systemically with adenoviruses encoding Ang-1 (AdAng-1), or control virus (AdEV). The mice were euthanized after 4 weeks of adenovirus treat-
ment and effects on early to intermediate atherosclerotic lesions was investigated. (A) Representative picture of Sudan IV en face (top panel) (n¼ 4 per
group). (B) Sudan IV en face staining was quantified from the beginning of aortic arch to the left common carotid artery using image analysis software and
expressed as the percentage lesion area in each vessel. **P< 0.001. (C) Oil red O-positive atherosclerotic areas were calculated by using ImageJ image analy-
sis software (n ¼ 12–15 per group). Atherosclerotic plaques were quantified as described in the legend to Figure 1. *P<0.05. (D) Similarly, three sections
from each animal were analysed for MOMA-2-positive lesion size (mm2) (n ¼ 12–15 per group). *P<0.05. Original magnification 2.5 (Sudan IV en face);
bars, 1 mm (Sudan IV).
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identified as a site for storage and rapid deployment of monocytes, which
contribute to atherosclerosis development.31 Interestingly, preliminary
study showed that proportion of bone marrow Ly6Chigh monocytes was
reduced following AdAng-1 treatment, whereas splenic Ly6Chigh mono-
cytes remained unchanged (data not shown), suggesting that Ly6Chigh
inflammatory monocytes are likely mobilized from bone marrow in
response to Ang-1.
3.4 Ang-1 increases plasma levels of VEGF
and MCP-1 in ApoE-/- mice fed a normal
chow diet
Chemokines such as MCP-1 is crucial for monocyte mobilization from
bone marrow.32 To test whether overexpression of Ang-1 alters circu-
lating cytokine/chemokine profiles, we analysed the plasma concentra-
tions of VEGF and MCP-1 by ELISA. Ang-1 significantly increased both
plasma VEGF (Figure 5A) and MCP-1 (Figure 5B) levels on day 3 and 10
after administration of viruses. Notably, the increased level of MCP-1
persisted even on day 28 when plasma Ang-1 concentrations had sub-
sided (Supplementary material online, Figure S1). Furthermore, the
plasma level of VEGF significantly correlated with expression of MCP-1
on day 10 in AdAng-1-treated but not in AdEV-treated animals
(Supplementary material online, Figure S2).
3.5 Ang-1 induces release of VEGF and
MCP-1 from aortic rings
Next, we performed aortic ring cultures to investigate the origin of
VEGF and MCP-1 upon stimulation with Ang-1. Ang-1 significantly
increased release of both VEGF and MCP-1 from aortic rings, and these
effects were blocked by pre-incubation with the Tie2 peptide (Figure 6),
suggesting that Ang-1 induces vascular cell expression of VEGF and
MCP-1, thereby creating a pro-remodelling environment in large vessels
in which atherosclerotic plaques form. In addition, expression of VEGF
and MCP-1 was significantly correlated with one another in these aortic
rings (Supplementary material online, Figure S3).
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Figure 3 Ang-1 increases circulating numbers of Gr1þmonocytes. Whole-blood samples were stained with CD11b, Gr1 and Ly6C antibodies and ana-
lysed by flow cytometry. (A) CD11b-positive cells were gated (R1) according to CD11b expression and side scatter. R1 cells were further divided into
SSClowCD11bþGr1-Ly6Clow monocytes (R2) and SSClowCD11bþGr1þLy6Chigh monocytes (R3) and SSChighCD11bþ Gr1highLy6Cinte neutrophils (R4). (B)
10 days after virus administration, the proportions of Gr1- and Gr1þ moncoytes in each treatment group was calculated as the percentage of total white
blood cells. (C) To correct for variability among individual experiments, the Gr1þ/Gr1- ratio was calculated for each treatment group. (D) The correlation
between MOMA-2-positive areas and Gr1þ and Gr1- monocytes on day 10 after AdAng-1 administration was analysed. Pooled data are presented from
three separate independent experiments (n¼ 4–5 per experiment). **P<0.01.
X 40 X 80
Figure 4 Ang-1 induces Ly6CþCD11bþmonocytes accumulation in
ApoE-/- mice fed a normal chow diet. Representative immunofluorescence
staining of Ly6C and CD11b monoclonal antibodies in AdAng1-treated
ApoE-/- mice. Red: Ly6C, green: CD11b, blue: 4’,6-diamidino-2-phenylin-
dole (DAPI). Original magnification, 40 (left),80 (right). White arrow
is the border line between arterial wall and plaque judging by out layer of
muscle filament. Yellow arrow is double staining mononuclear cell.
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.3.6 Ang-1 reduces cell-surface expression
of CD11b on Gr1þmonocytes
The b2-integrin heterodimer CD11b/CD18 (aMb2, also called Mac-1)
is one of the major adhesion molecules on monocytes that mediates
firm adhesion to endothelial cells via intercellular adhesion molecule-1
(ICAM-1).33,34 It is required for monocyte reverse migration and may
play a role in atherosclerosis development.35,36 Immunostaining of
ICAM1 at the sinus did not show any difference between control
virus-treated and AdAng-1-treated mice (Supplementary material
online, Figure S4). However, CC chemokine receptor 2 (CCR2)
expressions on circulating monocytes showed significant increase 10
days after AdAng-1 infection (data not shown), suggesting that Ang-1
may contribute to increased monocyte recruitment. To determine
whether the pro-atherogenic effects of Ang-1 are associated with
changes in b2-integrins on monocytes, we analysed the expression of
CD11b on circulating monocytes. Mice treated with AdAng-1 have
a significantly lower level of monocyte CD11b expression 10 days
after AdAng-1 treatment (Figure 7A). In addition, this Ang-1-induced
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Figure 5 Ang-1 increases plasma levels of VEGF and MCP-1 ApoE-/- mice fed a normal chow diet. Whole blood was collected at 3 and 10 and 28 days after
AdEV or AdAng-1 administration and plasma was isolated. ELISA was used to measure the level of VEGF (A) and MCP-1 (B). Pooled data are presented
from four independent experiments (n¼ 17–19 per group). **P< 0.01.
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Figure 6 Ang-1 induces the VEGF and MCP-1 release in conditioned medium from aortic ring. Thoratic artery from apoE-/- mouse was cut into 1 mm seg-
ments and aortic rings were stimulated with Ang-1 (400 ng/mL) with or without pre-incubation with Tie2 blocking peptide (NLLMAAS, 100 mM) for 30 min.
Medium containing 0.01% DMSO was served as vehicle control. The levels of VEGF (A) and MCP-1 (B) in conditioned medium were measured by ELISA
assay. Pooled data are presented from four independent experiments performed in duplicates.
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down-regulation of CD11b was Gr1þmonocyte specific (Figure 7B),
and the down-regulation of CD11b persisted up to 28 days after virus
administration, after expression of Ang-1 had declined
(Supplementary material online, Figure S5). Furthermore, there was a
significant negative correlation between CD11b and MOMA-2-posi-
tive lesion area in ApoE-/- mice (Figure 7C), suggesting a possible pro-
tective function of CD11b, which is inhibited by Ang-1, thereby
resulting in enhanced atherosclerosis in ApoE-/- mice.
To further investigate the mechanism by which down-regulation of
CD11b may reduce monocyte transmigration, we examined the interac-
tions of monocytes with human umbilical vein endothelial cells
(HUVECs). We found that blocking CD11b function with the monoclo-
nal antibody ICRF44 reduced monocytes reverse transmigration through
HUVEC monolayers by more than two-fold (IgG control; n¼ 3, transmi-
grated 15.70% vs. ICRF44; n¼ 3, transmigrated 32.43%, P¼ 0.068)
(Supplementary material online, Figure S6), suggesting that down-
regulation of CD11b expression on monocytes may lead to increased
monocyte retention.
In addition, we explored Tie2 expression in Gr1þCD11bþand
Gr1-CD11bþmonocytes and found that Tie2 expression was largely
restricted to Gr1þmonocytes compared to Gr1- monocytes in both
blood (Supplementary material online, Figure S7, 4.0006 0.1941 vs. 1.
9736 0.176; P< 0.01) and spleen (Supplementary material online, Figure
S7, 10.446 1.376 vs. 3.8926 0.3050; P< 0.01). Immunostaining of aorta
obtained from ApoE-/- mice received AdAng-1 treatment revealed that
Tie2-positive macrophages were present in the plaques (Supplementary
material online, Figure S8), suggesting that Ang-1/Tie2 pathway on mono-
cytes, is in part, responsible for Ang-1 pro-atherogenic effects.
4. Discussion
The activation of endothelial cells and the recruitment of monocytes are
key events in the early onset of atherosclerosis; however, these initial
processes may be reversible and typically do not cause clinical conse-
quences.1,37 It is the subsequent prolonged retention of monocytes/mac-
rophages in the intimal space and their uptake of oxidized LDL to form
foam cells that constitutes the major cellular component in early athero-
sclerotic lesion development.38 The major finding of this study is that sys-
temic overexpression of Ang-1 accelerates atherosclerosis development
in ApoE-/- mice. It has been shown that levels of Ang-1, but not of Ang-2,
are significantly increased in conditioned medium from cultured athero-
sclerotic arteries compared to healthy arteries.17 It has also been shown
that Tie2 expression is increased in atherosclerotic arteries compared to
healthy arteries. These findings support our results and suggest that the
Ang-1/Tie2 system has a significant role in the development of athero-
sclerosis. Although Ang-1 has been shown to have anti-inflammatory
properties in endothelial cells, our present study clearly demonstrates
pro-remodelling effects of Ang-1 on monocytes that translate into
increased atherosclerosis in the context of elevated cholesterol levels in
ApoE-/- mice. The mechanisms by which Ang-1 promotes atherosclero-
sis appear to involve (i) Ang-1-induced pro-remodelling cytokine release;
A B
C
Gr1- Gr1+
0
50
100
150
200
CD
11
b 
M
FI
AdEV  AdAng-1
**
30
40
50
60
CD
11
b 
M
FI
AdEV  AdAng-10
20
40
60
80
100
120
To
ta
l C
D1
1b
 M
FI
AdEV  AdAng-1
**
Figure 7 Ang-1 reduces cell-surface CD11b expression on Gr1þmonocytes. Whole-blood samples were stained with anti-CD11b and anti-Gr1 antibod-
ies, and analysed by flow cytometry as described in the legend to Figure 3. (A) CD11b expressions [median fluorescence intensity (MFI)] on circulating mono-
cytes in control and AdAng-1 groups were compared 10 days after virus administration. (B) CD11b expression on Gr1- and Gr1þ monocytes in control and
AdAng-1 groups were analysed and representative histograms were depicted. (C) The correlation between MOMA-2-positive areas and CD11b expression
on Gr1þ monocytes on day 10 after AdAng-1 administration was analysed. CD11b expression was represented by MFI. Pooled data are presented from
three independent experiments (n¼ 5 per experiment). **P<0.01.
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(ii) Ang-1 increases the proportion of circulating inflammatory mono-
cytes and (iii) Ang-1-mediated reduction in CD11b expression on mono-
cytes, resulting in increased monocyte/macrophage retention in
atherosclerotic plaques.
In the present study, plasma levels of VEGF and MCP-1, both of which
promote atherosclerosis in mice,39,40 are increased following systemic
overexpression of Ang-1. Ang-1 increased VEGF and MCP-1 release via
Tie2 from aortic rings suggesting that the inflammatory effects of Ang-1
are evident in large arteries, in which atherosclerotic plaques form.
Taken together our data suggest that Ang-1/Tie2 pathway participates in
the inflammatory process under these conditions. VEGF is a potent regu-
lator of vascular permeability.41 It not only stimulates endothelial cell
proliferation but also upregulates other pro-remodelling cytokines
release from endothelial cells, such as MCP-1.42 Ang-1-induced
increased levels of VEGF and MCP-1 are positively correlated with each
other in both in vivo and in vitro systems, suggesting Ang-1 can create a
positive pro-remodelling cytokine feedback loop in large arteries, which
resulted in sustained inflammation even after systemic Ang-1 levels
dropped to baseline 14 days after AdAng-1 injection (Supplementary
material online, Figure S1).
Hypercholesterolemia induces monocytosis and monocytes accumu-
lation in the plaques.43 Recently, the importance of neutrophil in early
atherosclerosis development has been increasingly recognized.44 Doring
et al.43 have demonstrated that the mechanism of neutrophil-driven
atherosclerosis is mediated through neutrophil granule protein
cathelicidin-induced inflammatory monocytes recruitment,45 suggesting
that bone marrow-derived monocytes are crucial in atherosclerosis
development. Hypercholesterolemia is known to induce selective
expansion of Gr1þ/Ly6Chigh monocytes in ApoE–/– mice, and these cells
preferentially adhere to activated endothelium, infiltrate the arterial wall
and develop into atherosclerotic macrophages.7 Ang-1 overexpression
leads to a reduction in the prevalence of Gr1þ/Ly6Chigh inflammatory
monocytes in bone marrow but an increase in circulation in AdAng-1-
treated animals, suggesting that Ang-1 may trigger monocyte mobiliza-
tion from bone marrow most likely through up-regulation of MCP-
1.32,40,46–49 The imbalance of monocyte subsets in circulation induced by
Ang-1 overexpression is associated with increased atheroma (Figure 3D).
In addition, we show for the first time that Gr1þ/Ly6Chigh not Gr1-/
Ly6Clow monocytes express Tie-2 in ApoE-/- mice (Supplementary mate
rial online, Figure S7). Until recently, Tie-2 was thought to be restricted
to endothelial cells. However, De Palma et al.48 identified a subset of Tie-
2-positive monocytes that promote angiogenesis in experimental
tumour model.50 Recently, studies have revealed that functions of Tie-2-
expressing monocytes (TEMs) may not be restricted to angiogenesis and
immunosuppression. TEMs are involved in inflammatory process.51,52
Our findings suggest that Ang-1/Tie2 is, in part, responsible for migra-
tion/recruitment of Gr1þ/CCR2þmonocytes in addition to MCP-1.
Furthermore, the presence of Ly6Cþ cells within atherosclerotic pla-
ques (Figure 4) provides further evidence that this group of cells is likely
to account for the observed accumulation of monocytes/macrophages,
which contributed to Ang-1-induced atherosclerosis development.
Adhesion molecules participating in monocyte–endothelial cell inter-
actions are known to play a critical role in atherogenesis.35 In this study,
we observed that overexpression of Ang-1 increased oil red-positive
lesion size and it is associated with down-regulation of CD11b expres-
sion on circulating Gr1þmonocytes. It has become increasingly clear
that the dynamic trafficking of monocyte-derived cells within athero-
sclerotic lesions is closely linked to disease progression.53 Prolonged
retention of monocytes/macrophages in the intimal space1,2 or reduced
rate of mononuclear cell emigration (i.e. reverse migration) from
lesions53 is crucial for atherosclerosis development. Reverse migration is
a physiological feature of human mononuclear phagocytes54 and that this
process is dependent on both ICAM-1 and CD18 (integrin b2).
54 Since
CD11b forms functional heterodimer complex with CD18, down-
regulation of CD11b expression is likely to affect monocyte reverse
migration and as a consequence would favour monocyte retention and
progression of atherosclerosis. Our assumption is supported by in vitro
study showing that blockade of CD11b function leads to reduced mono-
cyte reverse transmigration through endothelial cells and inverse corre-
lation between CD11b expression and plaque monocyte/macrophage
accumulation (Figure 7C). Merched et al.53 showed that b2 integrin defi-
ciency accelerates early atherosclerosis in LDLR/mice, suggesting that
CD11b may play a dynamic role in the development of atherosclerosis.
Interestingly, CD11b/CD18 activation has been proven to be able to
inhibit macrophage lipid uptake, and CD11b-deficient peritoneal macro-
phages have up-regulated level of CD36 expression, and lipid accumula-
tion compare to wild-type controls,54 suggesting that Ang-1-induced
down-regulation of CD11b may contribute to lipid accumulation in the
lesions.
In conclusion, Ang-1 overexpression induces MCP-1 and VEGF in cir-
culation and subsequently caused inflammatory monocyte mobilization,
and down-regulated CD11b expression on these cells, leading to mono-
cytes/macrophages accumulation and atherosclerotic plaque formation.
Our findings provide a novel mechanism by which Ang-1 may contribute
to atherosclerosis development.
Supplementary material
Supplementary material is available at Cardiovascular Research online.
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